{
    "medicine_id": "240ee8d769c44f61a0f6302ff9cb531bbc617624",
    "platform_id": "DB00507",
    "metadata": {
        "name": "Alinia 100 mg 5mL Powder for suspension",
        "composition": "100 mg 5mL Nitazoxanide",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of diarrhea in adults and children caused by the protozoa i Giardia lamblia i and for the treatment of diarrhea in children caused by the protozoan i Cryptosporidium parvum i FDA label Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV immunodeficiency FDA label A31973 A31976",
            "contraindications": {
                "disease": "Data on nitazoxanide overdosage is not available FDA label In studies in rodents and dogs the oral LD50 was higher than 10 000 mg kg One time oral doses of up to 4000 mg nitazoxanide have been given to healthy adult volunteers without severe adverse effects Gastric lavage may be appropriate soon after oral administration if overdose occurs Supportive and symptomatic treatment should also be administered FDA label According to previous studies FDA label less than 1 of the patients age 12 years and older participating in clinical trials with NTZ suffered from the following adverse effects Systemic asthenia fever pain allergic reaction pelvic pain back pain chills fever flu like syndrome Central Nervous System dizziness somnolence insomnia tremor hypesthesia Gastrointestinal System vomiting dyspepsia anorexia flatulence constipation dry mouth thirst Urogenital System discolored urine dysuria amenorrhea metrorrhagia kidney pain edema labia Metabolic Nutrition increased SGPT Hemic Lymphatic Systems anemia leukocytosis Skin rash pruritus Special Senses eye discoloration ear ache Respiratory System epistaxis lung disease pharyngitis Cardiovascular System tachycardia syncope hypertension Muscular System myalgia leg cramps spontaneous bone fracture",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation FDA label A31976 Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin flavodoxin oxidoreductase dependent electron transfer reaction an essential reaction need for anaerobic energy metabolism of various microorganisms Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited relieving symptoms of diahrrea L1425 Interference with the PFOR enzyme dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity FDA label A31973 L1425",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}